














**AMENDMENTS TO THE CLAIMS**



1. (withdrawn) A method of treating or preventing an amyloid-related disease in a subject comprising administering to a subject a therapeutically effective amount of a compound, wherein said compound is selected from the group consisting of  
*N*-(6-aminoheptyl)-4-bromobenzamidine (compound #145),  
4-bromo-*N*-{7-[(4-bromobenzimidoyl)-amino]-heptyl}-benzamide (compound #146),  
*N*-hydroxy-4-(9-hydroxyaminononyloxy)-benzamidine (compound #147),  
*N*-[7-(4-carbamimidoylbenzoylamino)-heptyl]-terephthalamic acid ethyl ester (compound #148),  
*N*-[9-(4-carbamimidoyl-benzoylamino)-nonyl]-terephthalamic acid ethyl ester (compound #149),  
4,4'-(pentamethylenediamidino)di(*p*-bromobenzene) (compound #150),  
4,4'-(nonamethylenediamidino)di(*p*-bromobenzene) (compound #151),  
4,4'-(nonamethylenediamidino)di(*p*-methoxybenzene) (compound #152),  
4-methoxy-*N*-{2-[2-(4-methoxyphenyl)-4,5-dihydroimidazol-1-yl]-ethyl}-benzamidine (compound #153),  
4,4'-(pentamethylenediamidino)di(*p*-methoxybenzene) (compound #154),  
2,2'-(*p*-amidinophenylcarboxamido)-*N,N*-diethyl-*p*-amidinobenzamide (compound #155),  
{4-[5-(*p*-aminophenoxy)-pentyloxy]-phenyl}-(4,5-dihydro-1*H*-imidazol-2-yl)-amine (compound #156),  
4,4'-(nonamethylenedisulfamyl)di(amidinobenzene) (compound #158),  
3,3'-(pentamethylenediaminocarbonyl)di(amidinobenzene) (compound #159),  
4,4'-(tetramethylenediaminocarbonyl)di(amidinobenzene) (compound #160), and  
pharmaceutically acceptable salts thereof.
2. (withdrawn) The method according to claim 1, wherein said subject is in need of treating or preventing of said amyloid-related disease.
3. (withdrawn) The method according to claim 2, wherein said amyloid-related disease is associated with IAPP.
4. (withdrawn) The method according to claim 2, wherein said amyloid-related disease is associated with  $\beta$ -amyloid.

5. (withdrawn) The method according to claim 2, wherein said amyloid-related disease is, Alzheimer's disease, Down's syndrome, type II diabetes, Mild Cognitive Impairment, age-related macular degeneration, or cerebral amyloid angiopathy.
6. (withdrawn) The method according to claim 2, wherein said compound is adapted to be administered orally.
7. (withdrawn) The method according to claim 2, where said subject is a human.
8. (previously presented) A chemical compound selected from the group consisting of:









and pharmaceutically acceptable salts thereof.

9-22. (cancelled)

23. (currently amended) A pharmaceutical composition comprising a compound according to claim 8, and a pharmaceutically acceptable vehicle.

24. (cancelled)

25. (previously presented) A pharmaceutical composition for the treatment or prevention of an amyloid-related disease comprising a therapeutically effective amount of a compound according to claim 8.

26. (original) The composition according to claim 25, wherein said amyloid-related disease is Alzheimer's disease, Down's syndrome, type II diabetes, Mild Cognitive Impairment, age-related macular degeneration, or cerebral amyloid angiopathy.